Open veterinary journal · 2024
The standardization and efficacy of fermented Crescentia cujete (L.) in combination with enrofloxacin against artificially induced pneumonic pasteurellosis in rat models.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prakoso Yos Adi, Susilo Achmadi, Widyarini Sitarina
Аннотация
BACKGROUND: Pasteurella multocida is an opportunistic bacterium that causes pneumonic pasteurellosis (PP). The common treatment against PP is using antibiotics in conjunction with nonsteroidal anti-inflammatory drugs (NSAIDs). This combination presents various complications, i.e., immune-depression. Hence, the alternative therapy to replace the effects of NSAIDs needs to be clarified. One of them is using fermented calabash [Crescentia cujete (L.)] (FCC).
AIM: This study aimed to elucidate the efficacy of FCC in combination with enrofloxacin against artificially induced PP in rat models.
METHODS: The calabash was collected and fermented. Moreover, the product of FCC was standardized regarding its biochemical compounds using Liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography. This study used 30 male Sprague Dawley rats, weighing 251.52 ± 2.65 grams, 6 months old. The rats were divided into six groups as follows: G1 (control); G2 (infected with Pasteurella multocida + untreated); G3 (infected + 20 mg/kg enrofloxacin); G4 (infected + 20 mg/kg enrofloxacin + 30 mg/kg ibuprofen); G5 (infected + 20 mg/kg enrofloxacin + 2.96 mg/kg FCC); and G6 (infected + 20 mg/kg enrofloxacin + 5.92 mg/kg FCC). The treatment was given once daily for 7 days. On day eight, the rats were radiographed. The serum was collected and tested against C-reactive protein (CRP) and procalcitonin. The rats were euthanized and lung tissue was collected for histopathology and immunohistochemistry against CD4+, CD8+, and COX-2. The data were analyzed using SPSS.
RESULTS: This study indicated that FCC contains choline, phytonadione, alpha-tocopherol, and retinol. Moreover, using FCC as a combination therapy with enrofloxacin against PP in group G6 promotes a repair of radiology image compared to other treatments (p < 0.05). Group G5 and G6 showed increased activity of bronchial-associated lymphoid tissue, immune expression of CD4+ and COX-2, and the level of CRP and procalcitonin within the lung tissue (p < 0.05). Group G6 indicated better effects in various parameters in this study. However, the FCC has not influenced the immune expression of CD8+ during PP (p > 0.05).
CONCLUSION: This study proved that FCC could be used in rat models as an alternative anti-inflammatory treatment in combination with enrofloxacin against PP. Further research is needed to explore other effects of FCC to support the current findings.
AIM: This study aimed to elucidate the efficacy of FCC in combination with enrofloxacin against artificially induced PP in rat models.
METHODS: The calabash was collected and fermented. Moreover, the product of FCC was standardized regarding its biochemical compounds using Liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography. This study used 30 male Sprague Dawley rats, weighing 251.52 ± 2.65 grams, 6 months old. The rats were divided into six groups as follows: G1 (control); G2 (infected with Pasteurella multocida + untreated); G3 (infected + 20 mg/kg enrofloxacin); G4 (infected + 20 mg/kg enrofloxacin + 30 mg/kg ibuprofen); G5 (infected + 20 mg/kg enrofloxacin + 2.96 mg/kg FCC); and G6 (infected + 20 mg/kg enrofloxacin + 5.92 mg/kg FCC). The treatment was given once daily for 7 days. On day eight, the rats were radiographed. The serum was collected and tested against C-reactive protein (CRP) and procalcitonin. The rats were euthanized and lung tissue was collected for histopathology and immunohistochemistry against CD4+, CD8+, and COX-2. The data were analyzed using SPSS.
RESULTS: This study indicated that FCC contains choline, phytonadione, alpha-tocopherol, and retinol. Moreover, using FCC as a combination therapy with enrofloxacin against PP in group G6 promotes a repair of radiology image compared to other treatments (p < 0.05). Group G5 and G6 showed increased activity of bronchial-associated lymphoid tissue, immune expression of CD4+ and COX-2, and the level of CRP and procalcitonin within the lung tissue (p < 0.05). Group G6 indicated better effects in various parameters in this study. However, the FCC has not influenced the immune expression of CD8+ during PP (p > 0.05).
CONCLUSION: This study proved that FCC could be used in rat models as an alternative anti-inflammatory treatment in combination with enrofloxacin against PP. Further research is needed to explore other effects of FCC to support the current findings.